Proteasome inhibitor TQB3602
Term · Oncology and biomedicine · MLC-T-ONC-016258
An orally bioavailable proteasome inhibitor (PI) with potential antineoplastic activity. Upon oral administration, proteasome inhibitor TQB3602 inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which leads to an accumulation of unwanted or misfolded proteins, the disruption of various cell signaling pathways, and resulting in the induction of apoptosis. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.
| Identifier | MLC-T-ONC-016258 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016258",
"term": "Proteasome inhibitor TQB3602",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable proteasome inhibitor (PI) with potential antineoplastic activity. Upon oral administration, proteasome inhibitor TQB3602 inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which leads to an accumulation of unwanted or misfolded proteins, the disruption of various cell signaling pathways, and resulting in the induction of apoptosis. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/proteasome-inhibitor-tqb3602/"
}
Record 13,743 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.